Systemic sclerosis & Raynaud's
Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis
An erratum to this article was published (Rheumatology (Oxford), 1 May 2025 ↗)
Authors' conclusion
Using serum determinations, the activation of the T1 IFN pathway showed strong correlations with inflammatory mediators and associations with clinical manifestations, especially skin fibrosis and ILD in SSc patients. However, activated IFN pathway was not predictive of ILD progression.
Study context
- Population
- Patients with SSc and healthy controls
- Participants
- 200 vs 29
- Exposure
- SSc patients vs healthy controls; patients with vs without a T1 IFN signature
- SScn = 200
- Healthy controlsn = 29reference
- Outcome
- Serum IFN-α2a concentrations (ultrasensitive electrochemiluminescence assay)
Methodological detailslongitudinal follow-up for interstitial lung disease (ILD) progression after 2 years
- Longitudinal follow-up for ILD progression after 2 years
Main finding
As reported in the abstract
P = 0.158
Observational data: associations, not effects.
Further findings
T1 IFN signature (IFN-α2a cut-off 15.9 fg/ml) · baseline
- Patients identified as having a T1 IFN signature in their circulation
- 62
Cytokines/chemokines, IFN signature vs no IFN signature · baseline
- Significantly higher CCL8, CCL19, CXCL10, CXCL11 and IL-1α with an IFN signature
IFN-α2a and T1 IFN-related chemokine score · baseline
- IFN-α2a concentrations strongly correlated with T1 IFN-related chemokine score
Phenotype association · baseline
- IFN values associated with both skin and ILD involvement
ILD progression · 2 years
- IFN not a predictive marker for ILD progression
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →